

May 13, 1965

Leonard B. Achor, Ph.D., M.D.  
Associate Director  
Clinical Research  
Sandoz Pharmaceuticals  
Hanover, New Jersey

Dear Dr. Achor:

I am pleased to enclose the report which you requested in your letter of April 30, 1965. The table enclosed carries only a single diagnosis for all of the subjects, since the patients selected for this study were selected from our "therapy resistant schizophrenic" population.

In each instance, the patients were brought to the EEG laboratory, observed for about one-half hour by the research team (which includes a psychiatrist, a resident physician, and two research nurses) and various rating scales were completed. LSD was administered by the physician in the dosage indicated and the EEG, EKG, EMG, and eye movement recordings done; and blood pressure measured continuously for one to two hours. In most of the subjects the EEG indicated the usual increase in average frequency and increased periods of desynchronization. In subjects receiving repeated administration of LSD, blood count, hemoglobin, urinalysis, and liver function tests were done every 2-3 weeks, and these have shown no abnormal findings to date.

The clinical changes observed were typically those induced by LSD including increased illusory sensations, alterations in affect and communication, and in some subjects at higher dosages, a disorganization both in thought and in performance. There were no unusual clinical effects, except that we noted the development of tolerance, especially when the dosages were administered in periods of less than five days.

There were no behavioral effects of a nature to be termed by us as "adverse."

In five subjects, the administrations have been in a sequence, with increasing dosages in an effort to determine

whether such administrations would have a clinical therapeutic effect. In this group of severe schizophrenics we are evaluating this data and continuing our study. The subjects in this treatment group are indicated in the enclosed list by the notation "Rx" in the first column.

I trust this is the information you have requested. Thank you very much for your co-operation in making this interesting compound available to us for our research programs, and your offer of assistance.

Sincerely yours,

Max Fink, M.D.  
Professor of Psychiatry

MF:jm  
Enclosure